The company announced it on Sunday and its the first firm that will manufacturing the vaccine locally.
Panacea Biotec is one of six companies who have collaborate with the Russian Direct Investment Fund (RDIF) and Russia’s sovereign wealth fund which is marketing the vaccine globally.
The company in a press release said on Sunday that it has received the license to produce Sputnik V at Baddi in Himachal Pradesh.
According to the press release the initial test batches produced at Panacea Biotec’s facilities at Baddi in Himachal Pradesh were earlier shipped to the Gamaleya Center in Russia for quality control.
They also said that the test batches have successfully passed all the checks for quality parameters both at the Gamaleya Center in Russia and at the Central Drug Laboratory at Kasauli in Himachal Pradesh, India.
The release further stated that the vaccine is based on a proven and well studied platform of human adenoviral vectors and uses two different vectors for the two shots in a course of vaccination, will provide immunity for a longer duration than vaccines which are using the same delivery mechanism for both the shots.
Sputnik V was registered in India under the emergency use authorisation procedure on April 12 and vaccination against the disease with the same started on May 14.